Bellicum Pharmaceuticals (United States)

Recent papers from Bellicum Pharmaceuticals (United States)

1. Appraisal of Circular Economy Adoption Among Small and Medium Enterprises (SMEs) in the Construction IndustryInternational Journal of Construction Education and Research · 2025
2. Nanotechnology-Assisted Phytoremediation of Heavy Metal Contaminated Soils: A State-of-the-Art Review on Recent Progress, Challenges, and Future DirectionsSoil and Sediment Contamination An International Journal · 2025
3. Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case reportFrontiers in Oncology · 2025
4. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trialNature Communications · 2024
5. Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity2024
6. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceFrontiers in Immunology · 2023
7. Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicityBlood · 2021
8. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 ProteinsMolecular Therapy · 2020
9. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cellsBlood Advances · 2020
10. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignanciesLeukemia · 2019
11. Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal SwitchesMolecular Therapy — Oncolytics · 2018
12. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T™ cells in advanced solid tumors: Preliminary results from a dose escalation studyAnnals of Oncology · 2018
13. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyJNCI Journal of the National Cancer Institute · 2018
14. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast CancerJAMA Oncology · 2018
15. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted TherapiesCancer Research · 2018
16. Adoptive Immunotherapy Using PRAME-Specific T Cells in MedulloblastomaCancer Research · 2018
17. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor ModelsCancer Discovery · 2017
18. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40Molecular Therapy · 2017
19. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1Blood · 2017
20. Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in MyelomaBlood · 2016